1. Home
  2. FLNT vs MAIA Comparison

FLNT vs MAIA Comparison

Compare FLNT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluent Inc.

FLNT

Fluent Inc.

HOLD

Current Price

$3.03

Market Cap

96.1M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.31

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNT
MAIA
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.1M
79.0M
IPO Year
2009
2022

Fundamental Metrics

Financial Performance
Metric
FLNT
MAIA
Price
$3.03
$1.31
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
32.3K
363.2K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
41.67
33.33
EPS
N/A
N/A
Revenue
$208,764,000.00
N/A
Revenue This Year
$5.89
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.87
52 Week High
$4.49
$3.19

Technical Indicators

Market Signals
Indicator
FLNT
MAIA
Relative Strength Index (RSI) 30.66 43.99
Support Level $2.95 $1.24
Resistance Level $3.05 $1.48
Average True Range (ATR) 0.21 0.06
MACD -0.10 -0.01
Stochastic Oscillator 8.52 15.71

Price Performance

Historical Comparison
FLNT
MAIA

About FLNT Fluent Inc.

Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: